Copyright
©The Author(s) 2017.
World J Gastroenterol. Aug 7, 2017; 23(29): 5379-5385
Published online Aug 7, 2017. doi: 10.3748/wjg.v23.i29.5379
Published online Aug 7, 2017. doi: 10.3748/wjg.v23.i29.5379
Figure 2 In patients with hepatocellular carcinoma, serum sodium concentration before treatment with tolvaptan was positively correlated with decreased body weight (%), while no significant correlation was seen in those without hepatocellular carcinoma.
HCC: Hepatocellular carcinoma.
- Citation: Miyazaki M, Yada M, Tanaka K, Senjyu T, Goya T, Motomura K, Kohjima M, Kato M, Masumoto A, Kotoh K. Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. World J Gastroenterol 2017; 23(29): 5379-5385
- URL: https://www.wjgnet.com/1007-9327/full/v23/i29/5379.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i29.5379